363 related articles for article (PubMed ID: 32997124)
1. Evaluation of a National Comprehensive Cancer Network Guidelines-Based Decision Support Tool in Patients With Non-Small Cell Lung Cancer: A Nonrandomized Clinical Trial.
Wu SY; Lazar AA; Gubens MA; Blakely CM; Gottschalk AR; Jablons DM; Jahan TM; Wang VEH; Dunbar TL; Wong ML; Chan JW; Guthrie W; Belkora J; Yom SS
JAMA Netw Open; 2020 Sep; 3(9):e209750. PubMed ID: 32997124
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
Jabbour SK; Berman AT; Decker RH; Lin Y; Feigenberg SJ; Gettinger SN; Aggarwal C; Langer CJ; Simone CB; Bradley JD; Aisner J; Malhotra J
JAMA Oncol; 2020 Jun; 6(6):848-855. PubMed ID: 32077891
[TBL] [Abstract][Full Text] [Related]
3. Clinical-Pathologic Correlation and Guideline Concordance in Resectable Non-Small Cell Lung Cancer.
Stokes SM; Massarweh NN; Stringham JR; Varghese TK
Ann Thorac Surg; 2019 Sep; 108(3):837-844. PubMed ID: 31026431
[TBL] [Abstract][Full Text] [Related]
4. Real world study for the concordance between IBM Watson for Oncology and clinical practice in advanced non-small cell lung cancer patients at a lung cancer center in China.
Yao S; Wang R; Qian K; Zhang Y
Thorac Cancer; 2020 May; 11(5):1265-1270. PubMed ID: 32191394
[TBL] [Abstract][Full Text] [Related]
5. Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
Song J; Wang L; Ng NN; Zhao M; Shi J; Wu N; Li W; Liu Z; Yeom KW; Tian J
JAMA Netw Open; 2020 Dec; 3(12):e2030442. PubMed ID: 33331920
[TBL] [Abstract][Full Text] [Related]
6. Adherence to the mediastinal staging guideline and unforeseen N2 disease in patients with resectable non-small cell lung cancer: Nationwide results from the Dutch Lung Cancer Audit - Surgery.
Bousema JE; Heineman DJ; Dijkgraaf MGW; Annema JT; van den Broek FJC
Lung Cancer; 2020 Apr; 142():51-58. PubMed ID: 32088606
[TBL] [Abstract][Full Text] [Related]
7. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology.
Ryu JS; Choi NC; Fischman AJ; Lynch TJ; Mathisen DJ
Lung Cancer; 2002 Feb; 35(2):179-87. PubMed ID: 11804691
[TBL] [Abstract][Full Text] [Related]
8. Lung Cancer Screening Decision Aid Designed for a Primary Care Setting: A Randomized Clinical Trial.
Schapira MM; Hubbard RA; Whittle J; Vachani A; Kaminstein D; Chhatre S; Rodriguez KL; Bastian LA; Kravetz JD; Asan O; Prigge JM; Meline J; Schrand S; Ibarra JV; Dye DA; Rieder JB; Frempong JO; Fraenkel L
JAMA Netw Open; 2023 Aug; 6(8):e2330452. PubMed ID: 37647070
[TBL] [Abstract][Full Text] [Related]
9. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
Howington JA; Blum MG; Chang AC; Balekian AA; Murthy SC
Chest; 2013 May; 143(5 Suppl):e278S-e313S. PubMed ID: 23649443
[TBL] [Abstract][Full Text] [Related]
10. Assessment of the External Validity of the National Comprehensive Cancer Network and European Society for Medical Oncology Guidelines for Non-Small-Cell Lung Cancer in a Population of Patients Aged 80 Years and Older.
Battisti NML; Sehovic M; Extermann M
Clin Lung Cancer; 2017 Sep; 18(5):460-471. PubMed ID: 28416124
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non-Small-Cell Lung Cancer.
Woodard GA; Wang SX; Kratz JR; Zoon-Besselink CT; Chiang CY; Gubens MA; Jahan TM; Blakely CM; Jones KD; Mann MJ; Jablons DM
Clin Lung Cancer; 2018 Jan; 19(1):58-64. PubMed ID: 28645632
[TBL] [Abstract][Full Text] [Related]
12. Patterns of care for non-small cell lung cancer patients in Belgium: A population-based study.
Verleye L; De Gendt C; Vrijens F; Schillemans V; Camberlin C; Silversmit G; Stordeur S; Van Eycken E; Dubois C; Robays J; Wauters I; Van Meerbeeck JP
Eur J Cancer Care (Engl); 2018 Jan; 27(1):. PubMed ID: 28833865
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic Yield of Staging Brain MRI in Patients with Newly Diagnosed Non-Small Cell Lung Cancer.
Kim M; Suh CH; Lee SM; Kim HC; Aizer AA; Yanagihara TK; Bai HX; Guenette JP; Huang RY; Kim HS
Radiology; 2020 Nov; 297(2):419-427. PubMed ID: 32840470
[TBL] [Abstract][Full Text] [Related]
14. Different administration routes of recombinant human endostatin combined with concurrent chemoradiotherapy might lead to different efficacy and safety profile in unresectable stage III non-small cell lung cancer: Updated follow-up results from two phase II trials.
Honglian M; Zhouguang H; Fang P; Lujun Z; Dongming L; Yujin X; Yong B; Liming X; Yirui Z; Xiao H; Jin W; Yue K; Lvhua W; Ming C
Thorac Cancer; 2020 Apr; 11(4):898-906. PubMed ID: 32068962
[TBL] [Abstract][Full Text] [Related]
15. Addition of Metformin to Concurrent Chemoradiation in Patients With Locally Advanced Non-Small Cell Lung Cancer: The NRG-LU001 Phase 2 Randomized Clinical Trial.
Skinner H; Hu C; Tsakiridis T; Santana-Davila R; Lu B; Erasmus JJ; Doemer AJ; Videtic GMM; Coster J; Yang AX; Lee RY; Werner-Wasik M; Schaner PE; McCormack SE; Esparaz BT; McGarry RC; Bazan J; Struve T; Paulus R; Bradley JD
JAMA Oncol; 2021 Sep; 7(9):1324-1332. PubMed ID: 34323922
[TBL] [Abstract][Full Text] [Related]
16. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology.
J Clin Oncol; 1997 Aug; 15(8):2996-3018. PubMed ID: 9256144
[TBL] [Abstract][Full Text] [Related]
17. Association of Survival With Adjuvant Chemotherapy Among Patients With Early-Stage Non-Small Cell Lung Cancer With vs Without High-Risk Clinicopathologic Features.
Pathak R; Goldberg SB; Canavan M; Herrin J; Hoag JR; Salazar MC; Papageorge M; Ermer T; Boffa DJ
JAMA Oncol; 2020 Nov; 6(11):1741-1750. PubMed ID: 32940636
[TBL] [Abstract][Full Text] [Related]
18. Neutrophilia as prognostic biomarker in locally advanced stage III lung cancer.
Schernberg A; Mezquita L; Boros A; Botticella A; Caramella C; Besse B; Escande A; Planchard D; Le Péchoux C; Deutsch E
PLoS One; 2018; 13(10):e0204490. PubMed ID: 30304046
[TBL] [Abstract][Full Text] [Related]
19. Development and Validation of a Deep Learning Model for Non-Small Cell Lung Cancer Survival.
She Y; Jin Z; Wu J; Deng J; Zhang L; Su H; Jiang G; Liu H; Xie D; Cao N; Ren Y; Chen C
JAMA Netw Open; 2020 Jun; 3(6):e205842. PubMed ID: 32492161
[TBL] [Abstract][Full Text] [Related]
20. Guideline-concordant Care Improves Overall Survival for Locally Advanced Non-Small-cell Lung Carcinoma Patients: A National Cancer Database Analysis.
Ahmed HZ; Liu Y; O'Connell K; Ahmed MZ; Cassidy RJ; Gillespie TW; Patel P; Pillai RN; Behera M; Steuer CE; Owonikoko TK; Ramalingam SS; Curran WJ; Higgins KA
Clin Lung Cancer; 2017 Nov; 18(6):706-718. PubMed ID: 28601387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
